Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
Source abstract
Abstract
Cyclic RGD peptide-functionalized reversibly core-crosslinked biodegradable poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-PCL) micelles (cRGD-RCCMs) were designed and developed for highly potent and targeted glioma chemotherapy. To achieve crosslinkable core, dithiolane-functionalized trimethylene carbonate (DTC) was incorporated into PCL block. Interestingly, cRGD-RCCMs displayed a high doxorubicin (DOX) loading content of ∼18wt%, small hydrodynamic size of ∼50nm, and excellent colloidal stability with minimum drug leakage under physiological conditions while fast DOX release under cytoplasmic-mimicking reductive environments. MTT, confocal microscopy and flow cytometry measurement results pointed out that cRGD-RCCMs with 30% cRGD surface density (cRGD30-RCCMs) showed an evident selectivity, efficient cytoplasmic drug release, and superior antitumor activity to clinically used pegylated liposomal doxorubicin (DOX-LPs) in αvβ3 integrin overexpressing U87MG glioblastoma cells. Strikingly, DOX-loaded cRGD30-RCCMs demonstrated a prolonged circulation time showing an elimination half-life of ∼4.7h, three times exceeding that of the non-crosslinked counterparts, and a remarkably enhanced tumor accumulation of 7.7%ID/g. Furthermore, in vivo therapeutic studies revealed that DOX-loaded cRGD30-RCCMs effectively suppressed tumor growth, significantly prolonged survival time, and lessened side effects in subcutaneous U87MG glioblastoma-bearing nude mice. These reversibly core-crosslinked multifunctional biodegradable micelles might be developed into advanced and clinically viable targeted anticancer nanomedicines. Statement of significance Nanomedicines based on biodegradable micelles and nanoparticles offer a most promising treatment for malignant tumors. The therapeutic outcomes of current nanomedicines are, however, trimmed by their instability, low tumor retention, inefficient tumor cell uptake, and inferior drug release control. We report herein that cRGD-functionalized, rapidly glutathione-responsive, and reversibly core-crosslinked biodegradable micellar doxorubicin based on PEG-PCL block copolymer mediates potent and targeted glioma chemotherapy, affording significantly better treatment efficacy and lower systemic toxicity than the non-crosslinked micellar doxorubicin and clinically used pegylated liposomal doxorubicin controls. These reversibly core-crosslinked multifunctional biodegradable micelles have emerged as a robust, simple, versatile, and safe nanoplatform that might elegantly bridge the gap between the scientific and translational anticancer nanomedicine research.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced Polymer Synthesis and Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Strategies for advancing cancer nanomedicine10.1038/nmat3792 ↗
2. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
3. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines10.1016/j.jconrel.2014.05.036 ↗
4. Progress of drug-loaded polymeric micelles into clinical studies10.1016/j.jconrel.2014.06.042 ↗
5. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗
6. Multicenter phase II trial of genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer10.1007/s10549-007-9591-y ↗
7. Multicenter phase II trial of genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer10.1093/annonc/mdm374 ↗
8. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile10.1126/scitranslmed.3003651 ↗
9. Challenges in design of translational nanocarriers10.1016/j.jconrel.2012.05.042 ↗
10. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery10.1038/nrd4333 ↗
11. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects10.1016/j.nantod.2012.08.005 ↗
12. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance10.1039/c3cs60048c ↗
13. Complete regression of xenograft tumors upon targeted delivery of paclitaxel via Pi-Pi stacking stabilized polymeric micelles10.1021/acsnano.5b00929 ↗
14. Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo10.1016/j.biomaterials.2014.07.018 ↗
15. Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma10.1016/j.actbio.2015.02.009 ↗
16. Core-shell-corona micelle stabilized by reversible cross-linkage for intracellular drug delivery10.1002/marc.200900863 ↗
17. Redox-sensitive shell cross-linked PEG-polypeptide hybrid micelles for controlled drug release10.1039/c2py00600f ↗
18. Reversibly stabilized multifunctional dextran nanoparticles efficiently deliver doxorubicin into the nuclei of cancer cells10.1002/anie.200904260 ↗
19. Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors10.1016/j.biomaterials.2014.05.041 ↗
20. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+human breast tumor xenografts10.1016/j.jconrel.2015.01.012 ↗
21. PH-sensitive polycarbonate micelles for enhanced intracellular release of anticancer drugs: a strategy to circumvent multidrug resistance10.1039/c3py01784b ↗
22. Cancer nanomedicine: from targeted delivery to combination therapy10.1016/j.molmed.2015.01.001 ↗
23. A holistic approach to targeting disease with polymeric nanoparticles10.1038/nrd4503 ↗
24. Combinatorial targeting polymeric micelles for anti-tumor drug delivery10.1039/C5TB00347D ↗
25. Self-regulated multifunctional collaboration of targeted nanocarriers for enhanced tumor therapy10.1021/bm5009348 ↗
26. Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer10.1016/j.biomaterials.2014.10.069 ↗
27. Fructose-coated nanoparticles: a promising drug nanocarrier for triple-negative breast cancer therapy10.1039/C4CC06651K ↗
28. Carbohydrate-specific uptake of fucosylated polymeric micelles by different cancer cell lines10.1021/acs.biomac.5b00299 ↗
29. Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer10.1016/j.actbio.2015.06.027 ↗
30. Targeted intracellular protein delivery based on hyaluronic acid-green tea catechin nanogels10.1016/j.actbio.2016.01.011 ↗
31. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status10.1016/j.addr.2013.08.012 ↗
32. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress10.1016/j.jconrel.2011.09.063 ↗
33. Polymeric micelle stability10.1016/j.nantod.2012.01.002 ↗
34. Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation10.1016/j.nantod.2015.01.005 ↗
35. Complexity and simplification in the development of nanomedicines10.2217/nnm.15.146 ↗
36. Stimuli-responsive polymers: biomedical applications and challenges for clinical translation10.1016/j.addr.2012.11.004 ↗
37. Lessons in simplicity that should shape the future of drug delivery10.1038/nbt.3366 ↗
38. Clinical translation of nanomedicine10.1021/acs.chemrev.5b00116 ↗
39. Cancer nanomedicines: closing the translational gap10.1016/S0140-6736(14)61457-4 ↗
40. Self-crosslinkable and intracellularly decrosslinkable biodegradable micelles: a robust, simple and multifunctional nanoplatform for high-efficiency targeted cancer chemotherapy10.1016/j.jconrel.2016.05.060 ↗
41. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: a superior alternative to doxil and caelyx?10.1016/j.jconrel.2016.08.022 ↗
42. CRGD-directed, NIR-responsive and robust AuNR/PEG-PCL hybrid nanoparticles for targeted chemotherapy of glioblastoma in vivo10.1016/j.jconrel.2014.07.054 ↗
43. CRGD-functionalized polymer micelles for targeted doxorubicin delivery10.1002/anie.200460800 ↗
44. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier10.1021/nn402662d ↗
45. CRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo10.1016/j.jconrel.2016.05.014 ↗
46. Squaric acid mediated chemoselective PEGylation of proteins: reactivity of single-step-activated alpha-amino poly(ethylene glycol)s10.1002/chem.201200182 ↗
47. Squaric acid mediated synthesis and biological activity of a library of linear and hyperbranched poly(glycerol)-protein conjugates10.1021/bm300103u ↗
48. Conjugation of transferrin to azide-modified CdSe/ZnS core-shell quantum dots using cyclooctyne click chemistry10.1002/anie.201202876 ↗
49. Doxorubicin and beta-lapachone release and interaction with micellar core materials: experiment and modeling10.3181/0702-RM-31 ↗
50. Fine tuning micellar core-forming block of poly(ethylene glycol)-block-poly(epsilon-caprolactone) amphiphilic copolymers based on chemical modification for the solubilization and delivery of doxorubicin10.1021/bm200375x ↗
51. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking10.1021/mp100269f ↗
52. Specific near-IR absorption imaging of glioblastomas using integrin-targeting gold nanorods10.1002/adfm.201002253 ↗
53. Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies10.1016/j.biomaterials.2007.08.047 ↗
54. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging10.1016/j.biomaterials.2011.12.030 ↗
55. A pharmacokinetics study of radiolabeled micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in a colon carcinoma-bearing mouse model10.1016/j.apradiso.2013.05.011 ↗
56. Density-tunable conjugation of cyclic RGD ligands with polyion complex vesicles for the neovascular imaging of orthotopic glioblastomas10.1088/1468-6996/16/3/035004 ↗